Amerise Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	0.06	-1.46	-1.19	5.49	-3.37
Other Operating Activities	-	-0	-	-	-
Change in Accounts Receivable	-	-	62.17	-62.17	-
Change in Accounts Payable	-	-	-62.66	57.85	-
Change in Other Net Operating Assets	30.65	-0.23	0.36	-0.56	-0.57
Operating Cash Flow	30.71	-1.69	-1.32	0.61	-3.94
Investment in Securities	-1.16	23.01	1.26	-16.51	23.3
Investing Cash Flow	-30.7	2.67	1.26	-1.51	3.89
Short-Term Debt Issued	-	-	0.07	0.83	-
Total Debt Issued	-	-	0.07	0.83	-
Short-Term Debt Repaid	-	-0.9	-	-	-
Total Debt Repaid	-	-0.9	-	-	-
Net Debt Issued (Repaid)	-	-0.9	0.07	0.83	-
Financing Cash Flow	-	-0.9	0.07	0.83	-
Miscellaneous Cash Flow Adjustments	-	-	-0	0	-
Net Cash Flow	0.01	0.08	0.01	-0.06	-0.06
Cash Income Tax Paid	0.02	-	-	-	-
Levered Free Cash Flow	30.7	-1.14	-1.17	-1.44	-2.68
Unlevered Free Cash Flow	30.7	-1.14	-1.17	-1.44	-2.68
Change in Working Capital	30.65	-0.23	-0.13	-4.88	-0.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.